Department of Cardiovascular Medicine, Catholic University, Rome, Italy.
Diabetes Care. 2012 Feb;35(2):196-7. doi: 10.2337/dc11-1255. Epub 2012 Jan 6.
Type 1 diabetes is associated with increased platelet reactivity. We investigated whether α-lipoic acid (ALA) has any effect on platelet reactivity in these patients.
We randomly assigned 51 type 1 diabetic patients to ALA (600 mg once daily) or placebo for 5 weeks. Platelet reactivity was evaluated by the PFA-100 method and by measuring CD41 and CD62 platelet expression. C-reactive protein (CRP) and 8-iso-prostaglandin F2α serum levels also were measured.
Baseline variables were similar in the two groups. After treatment, closure time was longer (P = 0.006) and CD62P platelet expression was lower, both before (P = 0.002) and after (P = 0.009) ADP stimulation in the ALA group compared with the placebo group. CRP and 8-iso-prostaglandin F2α levels showed no differences between the two groups.
Our data show that ALA reduces measures of platelet reactivity ex vivo in type 1 diabetic patients, independently of antioxidant or anti-inflammatory effects.
1 型糖尿病与血小板反应性增加有关。我们研究了α-硫辛酸(ALA)对这些患者血小板反应性是否有任何影响。
我们将 51 名 1 型糖尿病患者随机分为 ALA(600mg 每日一次)或安慰剂组,疗程为 5 周。通过 PFA-100 法和测定 CD41 和 CD62 血小板表达来评估血小板反应性。还测量了 C 反应蛋白(CRP)和 8-异前列腺素 F2α 的血清水平。
两组的基线变量相似。治疗后,ALA 组的闭合时间更长(P=0.006),ADP 刺激前后的 CD62P 血小板表达均更低(P=0.002 和 P=0.009)。两组间 CRP 和 8-异前列腺素 F2α 水平无差异。
我们的数据表明,ALA 可降低 1 型糖尿病患者的体外血小板反应性,与抗氧化或抗炎作用无关。